AAP
ELVN icon

Arax Advisory Partners’s Enliven Therapeutics ELVN Stock Holding History

Arax Advisory Partners’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.8K Buy
+331
New +$14.1K ﹤0.01% 4073
2026
Q1 		– Sell
-137
Closed -$2.11K – 3960
2025
Q4 		$2.11K Sell
137
-16
-10% -$319 ﹤0.01% 3242
2025
Q3 		$3.13K Buy
+153
New +$3.08K ﹤0.01% 2999
2025
Q1 		– Sell
-103
Closed -$2.32K – 2788
2024
Q4 		$2.32K Hold
103
– – ﹤0.01% 1979
2024
Q3 		$2.63K Hold
103
– – ﹤0.01% 1959
2024
Q2 		$2.41K Buy
+103
New +$2.17K ﹤0.01% 1899

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Arax Advisory Partners's ELVN Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 331 shares worth $16.8K. The stake represents ﹤0.01% of the portfolio and ranks #4073 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in ELVN as recently as Q4 2025.

Arax Advisory Partners first reported a position in ELVN in Q2 2024 and has held it in 6 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Arax Advisory Partners held 331 shares of Enliven Therapeutics worth $16.8K as of Q2 2026.
  • Enliven Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Enliven Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4073 holding.
  • Arax Advisory Partners first reported a position in Enliven Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.